{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:40:10Z","timestamp":1767908410925,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012679","name":"Institut de Cardiologie de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12265-025-10703-1","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:49:06Z","timestamp":1759164546000},"page":"1924-1931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bayesian Reanalysis of Mortality Outcomes in Cardiovascular Trials: Addressing Limitations of Traditional Significance Testing"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-578X","authenticated-orcid":false,"given":"Gis\u00e8le","family":"Nakhl\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anick","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"LeLorier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"10703_CR1","doi-asserted-by":"publisher","unstructured":"Wasserstein RL, Lazar NA. The ASA statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):129\u2013133. https:\/\/doi.org\/10.1080\/00031305.2016.1154108.","DOI":"10.1080\/00031305.2016.1154108"},{"issue":"4","key":"10703_CR2","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1161\/CIRCULATIONAHA.121.055393","volume":"144","author":"AD Althouse","year":"2021","unstructured":"Althouse AD, Below JE, Claggett BL, et al. Recommendations for statistical reporting in cardiovascular medicine: a special report from the American Heart Association. Circulation. 2021;144(4):e70\u201391.","journal-title":"Circulation"},{"issue":"3","key":"10703_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3758\/s13423-020-01798-5","volume":"28","author":"J van Doorn","year":"2021","unstructured":"van Doorn J, van den Bergh D, B\u00f6hm U, et al. The JASP guidelines for conducting and reporting a Bayesian analysis. Psychon Bull Rev. 2021;28(3):813\u201326. https:\/\/doi.org\/10.3758\/s13423-020-01798-5.","journal-title":"Psychon Bull Rev"},{"issue":"5","key":"10703_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1164\/rccm.202006-2381CP","volume":"203","author":"FG Zampieri","year":"2021","unstructured":"Zampieri FG, Casey JD, Shankar-Hari M, Harrell FE Jr, Harhay MO. Using Bayesian methods to augment the interpretation of critical care trials. An overview of theory and example reanalysis of the alveolar recruitment for acute respiratory distress syndrome trial. Am J Respir Crit Care Med. 2021;203(5):543\u201352.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10703_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41562-021-01177-7","volume":"5","author":"JK Kruschke","year":"2021","unstructured":"Kruschke JK. Bayesian analysis reporting guidelines. Nat Hum Behav. 2021;5(10):1282\u201391. https:\/\/doi.org\/10.1038\/s41562-021-01177-7.","journal-title":"Nat Hum Behav"},{"issue":"3","key":"10703_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"issue":"15","key":"10703_CR7","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","volume":"390","author":"JE M\u00f8ller","year":"2024","unstructured":"M\u00f8ller JE, Engstr\u00f8m T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390(15):1382\u201393.","journal-title":"N Engl J Med"},{"key":"10703_CR8","doi-asserted-by":"publisher","unstructured":"Harold J. Probability, statistics, and the theory of errors. Proc R Soc Lond A. 1933;140:523\u2013535. https:\/\/doi.org\/10.1098\/rspa.1933.0086.","DOI":"10.1098\/rspa.1933.0086"},{"key":"10703_CR9","doi-asserted-by":"crossref","unstructured":"Wijeysundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol 2009;62(1):13\u201321. e5. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0895435608002096?via%3Dihub","DOI":"10.1016\/j.jclinepi.2008.07.006"},{"issue":"12","key":"10703_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.7326\/0003-4819-130-12-199906150-00019","volume":"130","author":"SN Goodman","year":"1999","unstructured":"Goodman SN. Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med. 1999;130(12):1005\u201313.","journal-title":"Ann Intern Med"},{"issue":"5","key":"10703_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ejhf.2137","volume":"23","author":"J Tromp","year":"2021","unstructured":"Tromp J, Ponikowski P, Salsali A, et al. Sodium\u2013glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail. 2021;23(5):826\u201334.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10703_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"10703_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","volume":"21","author":"JJ McMurray","year":"2019","unstructured":"McMurray JJ, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium\u2013glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21(5):665\u201375.","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10703_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJ McMurray","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"16","key":"10703_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"2","key":"10703_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"14","key":"10703_CR17","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJMoa2307227","volume":"389","author":"H Thiele","year":"2023","unstructured":"Thiele H, Zeymer U, Akin I, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med. 2023;389(14):1286\u201397.","journal-title":"N Engl J Med"},{"issue":"14","key":"10703_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367","author":"H Thiele","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann F-J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287\u201396.","journal-title":"N Engl J Med"},{"issue":"25","key":"10703_CR19","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","volume":"377","author":"H Thiele","year":"2017","unstructured":"Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419\u201332.","journal-title":"N Engl J Med"},{"issue":"47","key":"10703_CR20","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1093\/eurheartj\/ehx363","volume":"38","author":"H Thiele","year":"2017","unstructured":"Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J. 2017;38(47):3523\u201331.","journal-title":"Eur Heart J"},{"issue":"10410","key":"10703_CR21","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S0140-6736(23)01607-0","volume":"402","author":"U Zeymer","year":"2023","unstructured":"Zeymer U, Freund A, Hochadel M, et al. Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials. Lancet. 2023;402(10410):1338\u201346.","journal-title":"Lancet"},{"key":"10703_CR22","doi-asserted-by":"publisher","unstructured":"Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024;390(24):2325\u201330. https:\/\/doi.org\/10.1056\/NEJMc2406255.","DOI":"10.1056\/NEJMc2406255"},{"key":"10703_CR23","doi-asserted-by":"publisher","unstructured":"Ouweneel, D, Eriksen, E, Sjauw, K. et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. JACC. 2017;69(3):278\u2013287. https:\/\/doi.org\/10.1016\/j.jacc.2016.10.022.","DOI":"10.1016\/j.jacc.2016.10.022"},{"issue":"9","key":"10703_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJM199908263410901","volume":"341","author":"JS Hochman","year":"1999","unstructured":"Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341(9):625\u201334.","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10703-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:20:02Z","timestamp":1765549202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10703-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10703"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10703-1","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal studies were carried out by the authors for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"No human studies were carried out by the authors for this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human subjects\/informed consent"}},{"value":"Drs. G. Nakhl\u00e9 and J. LeLorier have received grants from the Montreal Heart Institute for this project.Dr. J-C.Tardif reports grant from Amarin, grant from AstraZeneca, grant from Ceapro, grants, personal fees and minor equity interest from Dalcor Pharmaceuticals, grant from Esperion, grant from Ionis, grant from Merck, grants from Novartis, fees from Pendopharm, and grant and fees from Pfizer, outside the submitted work; in addition, Dr. Tardif has a patent \u201cGenetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent\u201d pending, a patent \u201cMethods for using low dose colchicine after myocardial infarction\u201d pending, a patent \u201cMethods of treating a coronavirus infection using colchicine\u201d pending, and a patent \u201cEarly administration of low-dose colchicine after myocardial infarction\" pending; Dr. Tardif has waived his rights in the colchicine patents and do not stand to gain financially.Dr. A. Dubois has no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}